Page last updated: 2024-11-08

5-hydroxyisourate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-hydroxyisouric acid : An oxopurine that is 5,7-dihydro-1H-purine-2,6,8(9H)-trione in which the hydrogen at position 5 is substituted by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID250388
CHEBI ID18072
SCHEMBL ID997117
SCHEMBL ID11959537
SCHEMBL ID20520131
SCHEMBL ID21383432
MeSH IDM0497943

Synonyms (20)

Synonym
5-hydroxy-3,7-dihydropurine-2,6,8-trione
nsc-69826
6960-30-1
nsc69826
5-hydroxy-5,7-dihydro-1h-purine-2,6,8(9h)-trione
CHEBI:18072
5-hydroxyisouric acid
5-hydroxyisourate ,
SCHEMBL997117
SCHEMBL11959537
5-hydroxy-2,3,5,6,7,8-hexahydro-1h-purine-2,6,8-trione
DTXSID10290591
Q2823232
SCHEMBL20520131
SCHEMBL21383432
unii-du6pj7l9bx
nsc 69826
du6pj7l9bx ,
5h-purine-2,5,6,8-tetrol
5,7-dihydro-5-hydroxy-1h-purine-2,6,8(3h)-trione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
oxopurine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Urate Degradation to Ureidoglycolate613
Urate Degradation to Glyoxylate714
urate degradation to allantoin I29
urate degradation to allantoin29
ureide biogenesis417

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (46.67)29.6817
2010's7 (46.67)24.3611
2020's1 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.25 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]